Anavex Life Sciences Corp (AVXL) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Anavex Life Sciences Corp stock $1.02, price $1.15, that is 11.3% below the price, quality 48 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Show moreShow less
It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome.
Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors.
The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy.
The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies.
Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Stock analysis
Anavex Life Sciences Corp (AVXL) currently trades at $1.15, while our model-based Fair Value estimate is $1.02, 11% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.6800 (bear) to $1.28 (bull), the price of $1.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Anavex Life Sciences Corp reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$46.4M in FY2025.
Key figures
Market cap $117M Micro · EPS (TTM) $−0.1400 · Return on equity −12.8% · Return on assets (EBIT) −35.7% (5-year average) · Free cash flow −$39.0M · Net cash $103M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 7 out of 100 (medium confidence).
What moves the price
The share trades about 84% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −11%, AVXL screens richer than that median.
Fair Value models
Bear$0.6800Fair Value $1.02Bull$1.28
Price $1.15 · Downside -11.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Compare Anavex Life Sciences Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 5/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−11.3% · Above median
Profitability
Return on assets−44.7% · Bottom 25%
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Anavex Life Sciences Corp Fair Value". https://www.fairvalue-calculator.com/stock/AVXL
Frequently asked questions
Is Anavex Life Sciences Corp (AVXL) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $1.02 versus a price of $1.15, about 11% lower (overvalued).
What is the fair value of AVXL?
Our model-based fair value for Anavex Life Sciences Corp is $1.02 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.15.
What is the quality score of AVXL?
Anavex Life Sciences Corp has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anavex Life Sciences Corp (AVXL)?
Our model-based price target is the fair value of $1.02 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $0.6800, optimistic scenario $1.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Anavex Life Sciences Corp stock forecast for 2026?
Our models put fair value at $1.02, about 11% lower versus a price of $1.15 (overvalued). Cautious scenario $0.6800, optimistic scenario $1.28. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Anavex Life Sciences Corp (AVXL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anavex Life Sciences Corp it is $1.02 per share (as of Nov 8, 2026), against a price of $1.15. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Anavex Life Sciences Corp stock overvalued or undervalued in 2026?
As of Nov 8, 2026, AVXL trades above its calculated fair value: price $1.15, fair value $1.02, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVXL?
No. The price is what the market pays today ($1.15); the fair value is what the company's own numbers justify ($1.02). For Anavex Life Sciences Corp the two are $0.1300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anavex Life Sciences Corp worth?
The market values Anavex Life Sciences Corp at about $117M (market capitalisation, as of Nov 8, 2026). Per share that is $1.15; our models calculate a fair value of $1.02 per share.
What do the bullish and bearish scenarios say about AVXL?
Our models span a range for Anavex Life Sciences Corp: cautious scenario $0.6800, base $1.02, optimistic $1.28 per share (as of Nov 8, 2026, price $1.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anavex Life Sciences Corp (AVXL)?
Balance-sheet figures for Anavex Life Sciences Corp (as of Nov 8, 2026): return on equity −12.8%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is AVXL from its 52-week high?
Anavex Life Sciences Corp trades at $1.15, about 84% below its 52-week high of $7.40 and 4% above the low of $1.11 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.02 is for.
Which stocks are comparable to Anavex Life Sciences Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anavex Life Sciences Corp stock attractive at the current price?
The data as of Nov 8, 2026: price $1.15, calculated fair value $1.02 (−11%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVXL calculated?
We run Anavex Life Sciences Corp through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Anavex Life Sciences Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anavex Life Sciences Corp (AVXL)?
The closing price on Nov 6, 2026 was $1.15. Our model-based fair value is $1.02, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anavex Life Sciences Corp right now?
A fairly wide model range ($0.6800 to $1.28) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Anavex Life Sciences Corp
How large is the market capitalisation of Anavex Life Sciences Corp (AVXL)?
The market capitalisation of Anavex Life Sciences Corp is $117M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Anavex Life Sciences Corp (AVXL)?
Earnings per share at Anavex Life Sciences Corp are $−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Anavex Life Sciences Corp (AVXL)?
The return on equity (ROE) of Anavex Life Sciences Corp is −12.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anavex Life Sciences Corp (AVXL)?
On an EBIT basis the return on assets of Anavex Life Sciences Corp is −35.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Anavex Life Sciences Corp (AVXL) generate?
The free cash flow of Anavex Life Sciences Corp is −$39.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Anavex Life Sciences Corp (AVXL) hold?
Anavex Life Sciences Corp holds more cash than debt, $103M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Anavex Life Sciences Corp in the live analysis
One click puts Anavex Life Sciences Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
